Syncona (LSE:SYNC) said its portfolio company Beacon Therapeutics has delivered a positive topline result from the Phase II/III pivotal VISTA trial for laru-zova, a gene therapy targeting X-linked retinitis pigmentosa (XLRP).
The London-listed life science investor holds a 38.4% stake in Beacon, valued at £183.4 million as of 30 June, before this result.
The trial met its FDA-endorsed primary endpoint, with 31.0% of high-dose patients and 24.1% of low-dose patients achieving a 15-letter improvement in low luminance visual acuity at 12 months, against no responders in the untreated control group.
XLRP affects more than 20,000 patients across the US and Europe and has no approved treatment, with sufferers typically progressing from night blindness to legal blindness by a median age of 45.
VISTA is the first pivotal trial in the condition to hit its FDA-endorsed endpoint, building on five years of clinical data from Beacon's earlier HORIZON, SKYLINE and DAWN studies.
Beacon plans to begin pre-submission talks with regulators and start a rolling Biologics License Application later this year.
Chris Hollowood, chief executive of Syncona Investment Management, said the milestone reflected "significant value" accessible in late-stage life science investing and "has the potential to drive significant NAV growth for Syncona".
The full dataset will be presented at the American Academy of Ophthalmology's Retina Subspecialty Day on 10 October, alongside a further Syncona announcement.
News Intelligence what this means for the company
Beacon Therapeutics, in which Syncona holds a 38.4% stake valued at £183.4 million, has met the FDA-endorsed primary endpoint in its Phase II/III VISTA trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa—a rare eye disease with no approved treatment affecting over 20,000 patients in the US and Europe. This is the first pivotal trial in the condition to hit its regulatory endpoint, and Beacon plans to begin pre-submission talks with regulators and file a rolling Biologics License Application later this year, positioning the asset for potential commercialisation.
The trial success represents one of four value inflection points Syncona flagged as expected by end-2026, and the CEO explicitly linked it to potential significant NAV growth. With the life science portfolio at £866.7 million and uninvested capital at £171.4 million, a successful regulatory path for Beacon could materially lift Syncona's net asset value, though the full dataset presentation on 10 October and regulatory timelines remain key near-term catalysts.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
